Metastatic Castration-resistant Prostate Cancer
190
66
94
48
Key Insights
Highlights
Success Rate
67% trial completion
Published Results
33 trials with published results (17%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
12.6%
24 terminated out of 190 trials
66.7%
-19.8% vs benchmark
12%
22 trials in Phase 3/4
69%
33 of 48 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 48 completed trials
Clinical Trials (190)
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC
Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC
A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
Intestinal Akkermansia Muciniphila in Prostate Cancer
PRostate Olaparib Real World Evidence Study
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors